

QIBA Profile:

Atherosclerosis Biomarkers Assessment - 2019

Stage: Initial authoring

When referencing this document, please use the following format:

QIBA Atherosclerosis Biomarkers Committee. Atherosclerosis Biomarkers Assessment – 2018. Quantitative Imaging Biomarkers Alliance. Available at: http://qibawiki.rsna.org/index.php/Profiles

Table of Contents

[1. Executive Summary 3](#_Toc528020250)

[2. Clinical Context and Claim(s) 4](#_Toc528020251)

[Clinical Context 4](#_Toc528020252)

[Discussion 6](#_Toc528020253)

[Claims 6](#_Toc528020254)

[3. Profile Requirements 8](#_Toc528020255)

[3.0. Subject Handling 9](#_Toc528020256)

[Discussion 9](#_Toc528020257)

[Specification 11](#_Toc528020258)

[3.1. Image Data Acquisition 12](#_Toc528020259)

[Discussion 12](#_Toc528020260)

[Specification Common to Arterial Beds 15](#_Toc528020261)

[Protocol Specification Unique to Coronary Arteries 15](#_Toc528020262)

[Protocol Specification Unique to Carotid Arteries 15](#_Toc528020263)

[3.2. Image Data Reconstruction 15](#_Toc528020264)

[Discussion 16](#_Toc528020265)

[Specification 17](#_Toc528020266)

[3.3. Image QA 17](#_Toc528020267)

[Discussion 17](#_Toc528020268)

[Specification 19](#_Toc528020269)

[3.4. Image Analysis 19](#_Toc528020270)

[Discussion 20](#_Toc528020271)

[Specification 20](#_Toc528020272)

[4. Assessment Procedures 21](#_Toc528020273)

[4.1. Assessment Procedure: In-plane Spatial Resolution 22](#_Toc528020274)

[4.2. Assessment Procedure: Voxel Noise 23](#_Toc528020275)

[4.3. Assessment Procedure: Vessel structure Bias and Linearity 23](#_Toc528020276)

[Obtain test image set 24](#_Toc528020277)

[Determine Measurands 24](#_Toc528020278)

[Calculate statistical metrics of performance 25](#_Toc528020279)

[4.4. Assessment Procedure: Tissue Characteristics Bias and Linearity 25](#_Toc528020280)

[Obtain test image set 25](#_Toc528020281)

[Determine Measurands 26](#_Toc528020282)

[Calculate statistical metrics of performance 26](#_Toc528020283)

[4.5. Assessment Procedure: Reader / Image Analysis Tool Variability 27](#_Toc528020284)

[Appendices 28](#_Toc528020285)

[Appendix A: Acknowledgements and Attributions 28](#_Toc528020286)

[Appendix B: Conventions and Definitions 30](#_Toc528020287)

[Appendix C: Imaging Resolution Details 31](#_Toc528020288)

[Appendix D: Measurands with Description and Units 34](#_Toc528020289)

[Appendix E: CT Angiography Signal Applicability and Published Performance 35](#_Toc528020290)

[Vessel Structure 35](#_Toc528020291)

[Tissue Composition 35](#_Toc528020292)

[References 38](#_Toc528020293)

# 1. Executive Summary

Currently, clinical application of (C)CTA and atherosclerosis imaging is widely available as a technique used as a first line investigation of coronary vascular disease and in carotid as a second line for assessment of the plaque structure in order to choose the therapeutic approach (best medical treatment or revascularization). Evaluation of atherosclerotic arterial plaque characteristics is currently based-on qualitative markers. However, the reproducibility of such findings is poor even among experts [[1](#_ENREF_1)]. While certain imaging biomarkers such as carotid stenosis and coronary calcium scores are well accepted in clinical practice, there are opportunities to add further biomarkers currently only applied in the research arena.

Quantitative imaging markers have been shown to have additive value above traditional qualitative imaging metrics and clinical risk scores regarding patient outcomes [[2](#_ENREF_2)]. However, many definitions and cut-offs are present in the current literature, therefore standardization of quantitative evaluation of CTA datasets is needed before becoming a valuable tool in daily clinical practice. In order to establish these biomarkers in clinical practice, techniques to standardize quantitative imaging across different manufacturers with cross-calibration is required. Moreover, post processing of atherosclerotic disease segmentation needs to be optimized and standardized.

The goal of a QIBA Profile is to help achieve a useful level of performance for a given biomarker. Profile development is an evolutionary, phased process; this Profile is in the initial authoring stage. The performance claims represent expert consensus and will be empirically demonstrated at a subsequent stage. Users of this Profile are encouraged to refer to the following site to understand the document’s context: <http://qibawiki>.rsna.org/index.php/QIBA\_Profile\_Stages.

The **Claim** (Section 2) describes the biomarker performance. The **Activities** (Section 3) contribute to generating the biomarker. Requirements are placed on the **Actors** that participate in those activities as necessary to achieve the Claim. **Assessment Procedures** (Section 4) for evaluating specific requirements are defined as needed.

This document is intended to help clinicians basing decisions on these biomarkers, imaging staff generating these biomarkers, vendor staff developing related products, purchasers of such products and investigators designing trials with imaging endpoints.

Note that this Profile document only states requirements to achieve the claim, not “requirements on standard of care.” Further, meeting the goals of this Profile is secondary to properly caring for the patient.

# 2. Clinical Context and Claim(s)

## ****Clinical Context****

Atherosclerosis is a major health concern for our aging population. The most significant underlying disease cause of mortality and morbidity in individuals older than 55 years and becoming the leading cause of death worldwide. Given the devastating impact of this widespread disease on individuals and population reflected in spiraling healthcare costs, biomarkers for better risk assessment and diagnosis at early stages, and monitoring of atherosclerosis will have a significant impact on public health. Noninvasive imaging biomarkers that would provide this information will have an impact to transform health care delivery and management. There is a critical gap in the biomarker qualification process, which needs to be addressed in order to move these quantitative imaging biomarkers forward.

The presence of atherosclerosis and the amount and type of arterial plaque have strong predictive value for acute events and for future cardiovascular events. Moreover, plaque composition may change dramatically over a few years and cardiovascular risk factors play a major role in these changes – changes that can be tracked with imaging. Further, recent evidences show that atherosclerosis is not only a progressive disease but it is possible to obtain also the plaque reversion. Intensive medical (lipid-lowering and anti-inflammatory) therapies may drive plaque reversion and conversion to a stable phenotype by strengthening the need to objectively quantify the amount and composition of the atherosclerotic plaque in order to monitor the plaque’s response to the therapies. Multiple platforms and approaches exist in plaque assessment. They included both qualitative and quantitative methods. Many of these methods have been associated with outcomes.

CT angiography (CTA) offers the potential to non-invasively detect, quantify and characterize atherosclerotic plaque. Accurate identification and quantification of plaque components using CTA is challenging because of the technical limitations of CTA and requires optimization of image quality, however, CTA may provide valuable information for characterization of plaques. Plaque composition is associated with the likelihood for rupture and downstream ischemic events, but is known to be highly variable presently. Standardized protocols and analysis of plaque characteristics can increase early identification of patients at increased risk for adverse events.

Plaque imaging has been widely used to show association with ACS in acute chest pain setting. Data on prognostic value for 2-4 year follow up are also available (e.g., PROMISE, CONFIRM). Atherosclerosis compositional imaging biomarkers allow earlier diagnosis, better prediction and more sensitive monitoring of vessel wall disease. In particular, compositional atherosclerotic biomarkers (lipid core, calcification, vessel wall area) represent quantitative measures that could reduce the size and duration as well as increase the objectivity of clinical, multi-center trials. The key advantage of these measures is earlier detection before atherosclerotic plaque progression and end organ symptom presentation.

While clearly the scanning protocols and approaches differ widely across different anatomies, e.g., chest vs. neck scanning, differences in the analysis of images post reconstruction have sometimes resulted in unnecessary fragmentation in analysis product offerings and inability to leverage histopathologic validation (of course differences in the hardware scanning protocols are appropriate; here we refer to the analysis of reconstructed data). The prevalence of carotid artery disease and CAD are closely related [[3](#_ENREF_3)]. Furthermore, carotid atherosclerosis has been shown to be an independent predictor for MACE, even in patients without pre-existing CAD [[4](#_ENREF_4)]. Such findings suggest a common underlying pathogenesis shared in both conditions, which is further supported by the Multi-Ethnic Study of Atherosclerosis (MESA) [[5](#_ENREF_5)]. Atherosclerosis develops progressively through continuous evolution of arterial wall lesions centered on the accumulation of cholesterol-rich lipids and the accompanying inflammatory response, which changes are closely similar in the coronary arteries, the carotid arteries, and even the aorta [[6](#_ENREF_6)]. Certain plaque characteristics such as large atheromatous core with lipid-rich content, thin fibrous cap, outward remodeling, infiltration of the plaque with macrophages and lymphocytes and thinning of the media are predisposing to vulnerability and rupture; and are similar in both carotid and coronary artery disease [[7](#_ENREF_7)].

Plaque composition is similar in coronary and carotid arteries, irrespective of its age, and this will largely determine relative stability [[8](#_ENREF_8)], suggesting similar presentation at CCTA as at CTA. Minor differences in the extent of the various plaque features may include a thicker fibrous cap and a higher prevalence of intraplaque hemorrhage and calcified nodules in the carotid arteries, however, without difference in the nature of plaque components [[7](#_ENREF_7)]. In addition, the carotid and coronary arteries have many similarities in the physiology of vascular tone regulation that has effect on plaque evolution [[9](#_ENREF_9)]. Myocardial blood perfusion is regulated by the vasodilation of epicardial coronary arteries in response to a variety of stimuli such as NO, causing dynamic changes in coronary arterial tone that can lead to multifold changes in coronary blood flow. In a similar fashion, carotid arteries are more than simple conduits supporting the brain circulation; they demonstrate vasoreactive properties in response to stimuli, including shear stress changes [[10](#_ENREF_10)]. Endothelial shear stress contributes to endothelial health and a favorable vascular wall transcriptomic profile [[11](#_ENREF_11)]. Clinical studies have demonstrated that areas of low endothelial shear stress in the coronary tree are associated with atherosclerosis development and high-risk plaque features [[12](#_ENREF_12)]. Similarly, in the carotid arteries lower wall shear stress is associated with plaque development and localization [[13](#_ENREF_13)].

It is important to acknowledge that technical challenges are different across beds (e.g. use of gating, vessel size, amount and nature of motion) – but these effects are mitigated by scan protocol, which result in approximate in-plane voxel sizes in the 0.5-0.75mm range, and the through-plane resolution of coronary (the smaller vessels) is actually better than, rather than inferior to, that of carotids (with the voxels being isotropic in coronary and not so in the neck and larger vessels extremities).

Conformance with this Profile by all relevant staff and equipment supports the following claims (see Disclaimer in Discussion below):

Claim 1: A true change in a lesion characteristic has occurred with 95% confidence if the measured measurand change is larger than 24% when the longest in-plane diameter is initially 50-100mm.

Claim 2: A true change in a lesion characteristic has occurred with 95% confidence if the measured measurand change is larger than 29% when the longest in-plane diameter is initially 35-49mm.

Claim 3: A true change in a lesion characteristic has occurred with 95% confidence if the measured measurand change is larger than 39% when the longest in-plane diameter is initially 10-34mm.

Claim 4:  The lesion characteristic measurement performance, expressed as within-lesion within-subject standard deviation (wSD), is 0.085, 0.103, and 0.141 respectively for lesions with diameters of 50-100mm, 35-49mm, and 10-34mm. The resulting 95% confidence interval for the true change in area for several example measured lesions is <fill in>

computed as , where and are the area measurements at baseline and the subsequent encounter, and and are the wSD estimates corresponding to these measurements.

These claims hold when:

* the lesion is measurable at both encounters (i.e., lesion margins are sufficiently conspicuous and geometrically simple enough to be recognized on all images in both encounters; the lesion is unattached to other structures of equal density)
* the lesion longest in-plane diameter is between 10 mm (area 0.5 mm2) and 100 mm (area 524 mm2) at both encounters

### Discussion

**Confidence Thresholds:** The 95% confidence thresholds (±24%, ±29%, ±39%) in Claims 1, 2 and 3 can be thought of as “error bars” or “noise” around the measurement of measurand change. If you measure change within this range, you cannot be certain that there has really been a change. However, if a lesion changes size beyond these limits, you can be 95% confident there has been a true change in the size of the lesion, and the perceived change is not just measurement variability. Note that this does not address the biological significance of the change, just the likelihood that the measured change is real.

**Clinical interpretation (progression/response):** The existence of a true change is described in Claims 1, 2 and 3 in terms of the minimum measured change required to be 95% confident a change has occurred. So, to be 95% confident there has been a true increase or decrease in lesion characteristic, the measured change should be at least 24% for a lesion that had a longest in-plane diameter of between 50mm and 100mm at baseline (and at least 29% or 39% for the next two size categories respectively).

**Clinical interpretation (magnitude of change):** The magnitude of the true change is described in Claim 4 in terms of the 95% Confidence Interval of the measured measurand change value. (See Confidence Interval of Result in section 3.1.2 below). If you measured the area to be 34 mm2 at baseline and 268 mm2 at follow-up (corresponding to a diameter change from 40mm to 80mm), then the 95% confidence interval for the true change is an increase in area of 234 mm2± 45. A confidence interval that contains zero indicates one should not conclude a true change has occurred.

While the claims have been informed by an extensive review of the literature and expert consensus that has not yet been fully substantiated by studies that strictly conform to the specifications given here. The expectation is that during field test, data on the actual field performance will be collected and appropriate revisions will be made to the claim or the details of the Profile. At that point, this caveat may be removed or re-stated.

### Claims

The performance values in Claims 1, 2, 3 and 4 reflect the likely impact of variations permitted by this Profile. The Profile requires that for a given lesion the same conformant Imaging Physician actor and image analysis tool actor must make the measurement at both encounters. If a different Imaging Physician and/or image analysis tool was used at the baseline, this means the current Imaging Physician and image analysis tool must repeat the baseline measurement for the result to be conformant with this profile. The profile permits the other actors (acquisition device, technologist, physicist, etc.) to differ at the two encounters, i.e. it is not required that the same scanner be used for both exams of a patient. If one or more of the actors that are permitted to differ are the same, the implementation is still conformant with this Profile and it is expected that the measurement performance will be improved. To give a sense of the possible improvement, the following table presents expected precision for alternate scenarios; however, except for the bolded column, these precision values are not Claims of this Profile. If the Imaging Physician or image analysis tool are different (or any other requirement of the profile is not met), the measurement might still be clinically useful, but the measurement is no longer conformant with the Profile and the measurement claims should not be presumed.

Table 2-1: Minimum Detectable Differences for Lesion Measurand changes (Informative)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lesion Diameter | Different  Acquisition Device | | | | Same  Acquisition Device | | | |
| Different  Imaging Physician | | Same  Imaging Physician | | Different  Imaging Physician | | Same  Imaging Physician | |
| Different Analysis Tool | Same Analysis Tool | Different Analysis Tool | Same Analysis Tool | Different Analysis Tool | Same Analysis Tool | Different Analysis Tool | Same Analysis Tool |
| >50mm | 43% | 24% | 43% | 24% | 37% | 10% | 37% | 8% |
| 35-49mm | 67% | 33% | 65% | 29% | 62% | 22% | 60% | 14% |
| 10-34mm | 139% | 120% | 80% | 39% | 136% | 117% | 75% | 28% |

Notes:

1. Acquisition Device actors being different means the scanner used at the two encounters were different models (from the same or different vendors). Two scanners with different serial numbers but of the same model are considered to be the same Acquisition Device actor.
2. Precision is expressed here as the repeatability or reproducibility coefficient, depending on the column.
3. A measured change in lesion characteristic that exceeds the relevant precision value in the table indicates 95% confidence in the presence of a true change.
4. Minimum detectable differences can be calculated from the following formula: 1.96 x sqrt(2 x wSD2), where wSD is estimated from the square root of the sum of the variances from the applicable sources of uncertainty (which makes the assumption that the variance components are additive, an assumption that has not yet been tested).
5. The estimates of the sources of variation were derived from several groundwork studies, some of which were performed on phantoms and some of which were performed on human subjects.

# 3. Profile Requirements

The Profile is documented in terms of “Actors” performing “Activities”. Equipment, image analysis tool software, staff or sites may claim conformance to this Profile as one or more of the “Actors” in the following table.

Conformant Actors shall support the listed Activities by conforming to all requirements in the referenced Section.

Table 3-1: Actors and Required Activities

|  |  |
| --- | --- |
| **Actor** | **Activity** |
| Acquisition Device | Image Data Acquisition |
| Reconstruction Software | Image Data Reconstruction |
| Image Analysis Tool | Image Analysis |
| Imaging Physician | Subject Handling |
| Image QA |
| Image Analysis |
| Physicist | Site Conformance and Periodic QA |
| Technologist | Subject Handling |
| Image Data Acquisition |
| Image Data Reconstruction |

Formal claims of conformance by the organization responsible for an Actor shall be in the form of a published QIBA Conformance Statement. QIBA Conformance Statements for Acquisition Devices, Reconstruction Software and Image Analysis Tools shall describe configuration settings or “Model-specific Parameters” (e.g. protocols) used to achieve conformance.

The requirements in this Profile do not codify a Standard of Care; they only provide guidance intended to achieve the stated Claim. Failing to conform to a “shall” in this Profile is a protocol deviation. Although deviations invalidate the Profile Claim, such deviations may be reasonable and unavoidable and the Imaging Physician or supervising physician is expected to do so when required by the best interest of the patient or research subject. How study sponsors and others decide to handle deviations for their own purposes is entirely up to them.

For the Acquisition Device, Reconstruction Software and Image Analysis Tool actors, while it will typically be the manufacturer who claims the actor is conformant, it is certainly possible for a site to run the necessary tests/checks to confirm conformance and make a corresponding claim. This might happen in the case of an older model device which the manufacturer is no longer promoting, but which a site needs a conformance claim to participate in a clinical trial.

The Physicist actor represents the person at the site responsible for managing the equipment performance related specifications. At some sites this will be a staff physicist, and at other sites it may be a person who manages a contractor or a service provided by a vendor.

The method for assessing atherosclerosis may be described as a pipeline. Subjects are prepared for scanning, raw image data is acquired, and images are reconstructed and evaluated. Such images may be obtained at (only) one encounter, or multiple longitudinally. When multiple encounters are available, in additional to assessing the disease at each individual encounter (referred to as a “cross sectional” claim) mage analysis may further assess the degree of change between the available encounters. When expressed as a percentage, change is the difference for a given measurand between the encounters divided by that at encounter 1. Although this introduces some asymmetry (e.g., measurements of 50mm2 and 100mm2 represent either a 100% increase or a 50% decrease depending on which was measured first), it is more familiar to clinicians than using the average of the two encounters as the denominator.

The Profile does not intend to discourage innovation, although it strives to ensure that methods permitted by the profile requirements will result in performance that meets the Profile Claims. The above pipeline provides a reference model. Algorithms which achieve the same result as the reference model but use different methods may be permitted, for example by directly measuring the change between two image sets rather than measuring the absolute measurands separately. Developers of such algorithms are encouraged to work with the appropriate QIBA committee to conduct any groundwork and assessment procedure revisions needed to demonstrate the requisite performance.

The requirements included herein are intended to establish a baseline level of capabilities. Providing higher performance or advanced capabilities is both allowed and encouraged. The Profile does not intend to limit how equipment suppliers meet these requirements.

## 3.1. Subject Handling

This activity involves handling each imaging subject at each encounter. It includes subject handling details that are necessary to reliably meet the Profile Claims.

### Discussion

This Profile will refer primarily to “subjects”, keeping in mind that the requirements and recommendations apply to patients in general, and subjects are often patients too.

**Timing Relative to Index Intervention Activity**: When the Profile is being used in the context of a clinical trial, refer to relevant clinical trial protocol for further guidance or requirements on timing relative to index intervention activity.

It is important that the **Contrast Protocol** achieves a consistent phase and degree of enhancement. Bolus tracking is a good tool if available, but is not required. When using bolus tracking, be consistent between encounters with where the ROI used for triggering is placed and the threshold used to trigger the scan. When bolus tracking is not available, be consistent between the encounters with the contrast volume, rate, scan timing after injection, and use (or lack) of a saline flush.

**Subject Positioning**: Positioning the subject Supine/Arms Up/Feet First has the advantage of promoting consistency (if it’s always the same, then it’s always consistent with baseline), and reducing cases where intravenous lines go through the gantry, which could introduce artifacts. Consistent positioning avoids unnecessary changes in attenuation, changes in gravity induced shape and fluid distribution, or changes in anatomical shape due to posture, contortion, etc. Significant details of subject positioning include the position of their arms, the anterior-to-posterior curvature of their spines as determined by pillows under their backs or knees, the lateral straightness of their spines. Prone positioning is not recommended. The sternum should be positioned over the midline of the table. The Table Height and Centering should be adjusted so that the midaxillary line is at the widest part of the gantry.

Positioning the chest (excluding the breasts) in the center of the gantry improves the consistency of relative attenuation values in different regions of the lung, and should reduce scan-to-scan variation in the behavior of dose modulation algorithms. The subject should be made comfortable, to reduce the potential for motion artifacts and to facilitate compliance with breath holding instructions.

When the patient is supine, the use of positioning wedges under the knees and head is recommended so that the lumbar lordosis is straightened and the scapulae are both in contact with the table. However, the exact size, shape, etc. of the pillows is not expected to significantly impact the Profile Claims. It is expected that clinical trial documentation or local clinical practice will specify their preferred patient positioning. An approach that promotes scan-to-scan consistency is essential.

When imaging head and neck lesions, it is not unusual to use gantry tilt, or positioning aids to adjust the slice orientation in the head and neck. Again, it is important to achieve reasonable consistency over encounters for a given patient.

The Subject Handling specification does not place requirements on patient positioning directly, but rather has the Imaging Physician disqualify measurements from the profile when the positioning at the two encounters is different. Consistent positioning will help ensure the majority of studies are conformant and thus achieve the profile Claim.

Recording the Subject Positioning and Table Heights in the image header is helpful for auditing and repeating baseline characteristics. Bismuth breast shields (used by some to reduce radiation exposure in the diagnostic CT setting) increase image noise. The effects of breast shields on image quality may vary depending on the types of shields and their positioning on the chest. The American Association of Physicists in Medicine currently does not endorse the use of breast shields, recommending the use of other dose reduction methods, such as dose modulation techniques, instead (https://www.aapm.org/publicgeneral/BismuthShielding.pdf). Thus, the use of breast shields is not recommended for this Profile. If used, position things such as breast shields so they do not degrade the reconstructed images.

Artifact sources, in particular metal and other high density materials, can degrade the reconstructed measurand data such that it is difficult to determine the true contour of a lesion. Due to the various scan geometries, artifacts can be induced some distance from the artifact source. The simplest way to ensure no degradation of the measurand data is to remove the artifact sources completely from the patient during the scan, if feasible.

Consistent centering of the patient avoids unnecessary variation in the behavior of dose modulation algorithms during scan.

Stents …

Use of **beta blockers** is recommend to achieve a target heart-rate < 75 bpm, and ideally a heart-rate < 60 bpm. On average, a higher heart-rate results in reduced measurand precision within the coronary arteries.

**Breath holding** reduces motion that might degrade the image and can lead to decrease in the heart rate during the scan. Stable breath hold and no motion of the chest or other body parts are critical for optimized image quality.

For coronary CT angiography imaging, breath holding commands are typically pre-recorded to allow for standard duration between initiation of the breath holding commands and scan start. This is important as the breath holding commands need to be coordinated with optimal contrast timing.

Breath holding reduces motion artefacts and also decreases heart rate, which are beneficial for coronary imaging.

Since a few seconds are needed for inspiration to lower heart rate, it is advised to wait  at least 4 second between initiation of the breathing instructions and the start of the mage acquisition.

To promote patient compliance, performing a practice round of the breathing instructions prior to moving the patient into the scanner also is strongly recommended.

Sample breathing instructions:

1. “Take in a deep breath and hold” (wait at least for seconds, then initiate the scan)
2. When scan is completed, say “You can breathe normally”

“here we may address the issue of bolus tracking vs. test bolus technique – with bolus tracking, typically only breath in and hold your breath, i.e. one cycle is possible. For test bolus technique, two cycles of breath in are possible” – we can discuss during the call whether to include this level of detail or not

“Appropriate” contrast means …….. hemorrhage, ulceration, intimal calcification

### Specification

| **Parameter** | **Actor** | **Requirement** |
| --- | --- | --- |
| Contrast Protocol | Imaging Physician | Shall prescribe a contrast protocol that achieves enhancement consistent with baseline. |
| Use of intravenous contrast | Imaging Physician | Shall determine whether the selected contrast protocol, if any, will achieve appropriate lumen conspicuity. |
| Technologist | Shall use the prescribed intravenous contrast parameters. |
| Artifact Sources | Technologist | Shall remove or position potential sources of artifacts (specifically including breast shields, metal-containing clothing, EKG leads and other metal equipment) such that they will not degrade the reconstructed CT image. |
| Table Height & Centering | Technologist | Shall adjust the table height for the mid-axillary plane to pass through the isocenter.  Shall position the patient such that the “sagittal laser line” lies along the sternum (e.g. from the suprasternal notch to the xiphoid process). |
| Nitrates | Technologist | Application of nitroglycerin |

### Protocol Specification Unique to Coronary Arteries

| **Parameter** | **Actor** | **Requirement** |
| --- | --- | --- |
| Breath hold | Technologist | Shall instruct the subject in proper breath-hold and start image acquisition shortly after full inspiration, taking into account the lag time between full inspiration and diaphragmatic relaxation. |

## 3.2. Image Data Acquisition

This activity involves the acquisition of image data for a subject at either encounter. It includes details of data acquisition that are necessary to reliably meet the Profile Claims.

### Discussion

Diagnostic image quality is impacted by both uncontrollable factors (heart-rate, plaque material composition, plaque morphology, etc.) and controllable factors (kVp, radiation dose, spatial resolution, etc.).

Excellent image quality is very important for the reliable detection and quantification of coronary atherosclerotic plaque. The standardization of image quality has to be achieved in the clinical trials of coronary CT angiography, which include the assessment of coronary plaque and evaluation of plaque progression. The image acquisition should be performed with the same tube potential if evaluation of CT attenuation is planned. The scan parameters should be adjusted to permit low image noise and high tissue contrast.

A given factor combination and its associated interdependencies will determine the achievable measurement precision and bias for a given measurand (stenosis, lumen area, etc.). The ideal estimator is a mathematical framework, derived from information theory, which provides a quantitative method to ascertain the impact of each factor on overall measurement performance. Utilizing this method, limits were set on all controllable factors to achieve a prescribed level of accuracy and precision under a range of typical uncontrollable factor conditions.

An example table that could be discussed in a future conference call

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Vessel Radius | kVp | Plaque Composition | Plaque Morphology | Luminal Enhancement | Rotation Time | Heart-rate | Pixel Size | MTFf50  (Resolution) | Noise (σ) | Stenosis wSD |
| 1.25 | 120 | Calcified | Concentric | 200HU | 350ms | **75bpm** | .625 | .3843 | 39 | 7.5% |
| 1.25 | 120 | Calcified | Concentric | 200HU | 350ms | **60bpm** | .625 | .3843 | 39 | 6.6% |
| 1.25 | 120 | Calcified | Concentric | 200HU | 500ms | **75bpm** | .625 | .3843 | 39 | 8.7% |
| 1.25 | 120 | Calcified | Concentric | 200HU | 350ms | **60bpm** | .625 | .3843 | 25 | 5% |

### Specification Common to Arterial Beds

| **Parameter** | **Actor** | **Requirement** | **DICOM Tag** |
| --- | --- | --- | --- |
| Acquisition Protocol | Imaging Physician | Shall prepare a protocol to meet the specifications in this table.  Shall ensure technologists have been trained on the requirements of this profile. |  |
| Acquisition Protocol | Acquisition Device | Shall be capable of making validated protocols (designed and validated by the manufacturer and/or by the site) available to the technologist at scan time. |  |
| Acquisition Device | Shall validate that the protocol achieves an f50 value that is between 0.3 mm-1 and 0.5 mm-1 for both air and soft tissue edges.  See section 4.1. Assessment Procedure: In-plane Spatial Resolution |  |
| Acquisition Device | Shall validate that the protocol achieves:   * a standard deviation that is < 20HU.   See 4.2. Assessment Procedure: Voxel Noise |  |
| Acquisition Protocol | Technologist | Shall select a protocol that has been previously prepared and validated for this purpose. |  |

### Protocol Specification Unique to Coronary Arteries

| **Parameter** | **Actor** | **Requirement** | **DICOM Tag** |
| --- | --- | --- | --- |
| Total Collimation Width | Imaging Physician | Shall set to Greater than or equal to 40mm. | Total Collimation Width (0018,9307) |
| Nominal Tomographic Section Thickness (T) | Imaging Physician | Shall set to Less than or equal to 1.0mm. | Single Collimation Width (0018,9306) |
| Scan Duration | Imaging Physician | Shall achieve a table speed of at least 4cm per second, if table motion is necessary to cover the required anatomy. | Table Speed (0018,9309) |
| Revolution Time | Imaging Physician | <fill in spec> | Revolution Time (0018,9305) |
| ECG Triggering | Imaging Physician | Shall be enabled with trigger set for end diastolic |  |

### Protocol Specification Unique to Carotid Arteries

| **Parameter** | **Actor** | **Requirement** | **DICOM Tag** |
| --- | --- | --- | --- |
| Total Collimation Width | Imaging Physician | Shall set to Greater than or equal to 16mm. | Total Collimation Width (0018,9307) |
| Nominal Tomographic Section Thickness (T) | Imaging Physician | Shall set to Less than or equal to 1.0mm. | Single Collimation Width (0018,9306) |
| Scan Duration | Imaging Physician | Shall achieve a table speed of at least 4cm per second, if table motion is necessary to cover the required anatomy. | Table Speed (0018,9309) |
| Localizer | Technologist | Shall confirm on the localizer (scout) image the absence of artifact sources that could affect the planned volume acquisitions or alter the attenuation of lung nodules. |  |

## 3.3. Image Data Reconstruction

This activity involves the reconstruction of image data for a subject encounter. It includes criteria and procedures related to producing images from the acquired data that are necessary to reliably meet the Profile Claims.

### Discussion

Note that the requirement to "select a protocol that has been prepared and validated for this purpose" is not asking the technologist to scan phantoms before every patient, or to validate the protocol themselves. Sites are required to have validated the protocols that the technologist will be using and conformance with the protocol depends on the technologist selecting those protocols.

**Reconstruction Protocol** affects the image pixel characteristics. The selection and reporting requirements imply a need for a method to record and communicate the protocol selected and any significant modifications and make that information available to the Imaging Physician for the QA Activity. The Profile does not dictate any specific method. Manual methods are acceptable.

**Reconstruction Field of View** affects reconstructed pixel size because the fixed image matrix size of most reconstruction algorithms is 512x512. If it is necessary to expand the field of view to encompass more anatomy, the resulting larger pixels may be insufficient to achieve the claim. A targeted reconstruction with a smaller field of view may be necessary, but a reconstruction with that field of view would need to be performed for every encounter. Pixel Size directly affects voxel size along the subject x-axis and y-axis. Smaller voxels are preferable to reduce partial volume effects and provide higher measurement precision.

Pixel size in each dimension is not the same as spatial resolution in each dimension. The spatial resolution of the reconstructed image depends on a number of additional factors including a strong dependence on the reconstruction kernel, however since the kernel is configured in the protocol, its effect on the spatial resolution will have been evaluated by the f50 requirement when determining conformance.

**Reconstructed Image Thickness** is the nominal width of the reconstructed image along the z-axis (reconstructed image thickness) since the thickness is not technically the same at the middle and at the edges.

**Reconstructed Image Interval** is the distance between two consecutive reconstructed images. An interval that results in discontiguous data is unacceptable as it may “truncate” the spatial extent of the lesion, degrade the identification of lesion contours, confound the precision of measurement for total lesion measurands, etc. Decisions about overlap (having an interval that is less than the nominal reconstructed slice thickness) need to consider the technical requirements of the clinical trial, including effects on measurement, throughput, image analysis time, and storage requirements.

Reconstructing datasets with **overlap** will increase the number of images and may slow down throughput, increase reading time and increase storage requirements. For multi-detector row CT (MDCT) scanners, creating overlapping image data sets has NO effect on radiation exposure; this is true because multiple reconstructions having different kernel, slice thickness and intervals can be reconstructed from the same acquisition (raw projection data) and therefore no additional radiation exposure is needed.

**Reconstruction Characteristics** influence the texture and the appearance of lesions in the reconstructed images, which may influence measurements. A softer kernel can reduce noise at the expense of spatial resolution. An enhancing kernel can improve resolving power at the expense of increased noise. Kernel characteristics also interact with acquisition parameters and reconstruction algorithm types; a sharper kernel in a low-dose scan might make a greater difference with an FBP Algorithm than with an Iterative Algorithm. The characteristics of different tissues (e.g. lung) may call for the use of different kernels, and implementers are encouraged to use kernels suitable for the anatomic region and tissue imaged. The use of multiple kernels in a single study is not prohibited by the specification below, but any given lesion must be measured on images reconstructed using consistent kernels at each encounter.

### Specification

| **Parameter** | **Actor** | **Requirement** | **DICOM Tag** |
| --- | --- | --- | --- |
| Reconstruction Protocol | Imaging Physician | Shall prepare a protocol to meet the specifications in this table.  Shall ensure technologists have been trained on the requirements of this profile. |  |
| Reconstructed Image Thickness | Imaging Physician | Shall set to between 0.5mm and 2.5mm (inclusive). | Slice Thickness (0018,0050) |
| Reconstructed Image Interval | Imaging Physician | Shall set to less than or equal to the Reconstructed Image Thickness (i.e. no gap, may have overlap). | Spacing Between Slices (0018,0088) |
| In-plane Spatial Resolution | Physicist | Shall validate that the protocol achieves an f50 value that is between 0.3 mm-1 and 0.5 mm-1 for both air and soft tissue edges.  See section 4.1. Assessment Procedure: In-plane Spatial Resolution |  |
| Voxel Noise | Physicist | Shall validate that the protocol achieves:   * a standard deviation that is < 60HU.   See section 4.2. Assessment Procedure: Voxel Noise |  |
| Reconstruction Protocol | Reconstruction Software | Shall be capable of performing reconstructions and producing images with all the parameters set as specified "Protocol Design Specification". |  |
| Image Header | Reconstruction Software | Shall record in the DICOM image header the actual values for the tags listed in the DICOM Tag column "Protocol Design Specification" as well as the model-specific Reconstruction Software parameters utilized to achieve conformance. |  |
| Reconstruction Protocol | Technologist | Shall select a protocol that has been previously prepared and validated for this purpose. |  |
| Reconstructed Image Thickness | Technologist | Shall set to between 0.5mm and 2.5mm (inclusive) if not set in the protocol. |  |
| Reconstructed Image Interval | Technologist | Shall set to less than or equal to the Reconstructed Image Thickness (i.e. no gap, may have overlap) and consistent with baseline. |  |
| Reconstruction Field of View | Technologist | Shall ensure the Field of View spans at least the full extent of the thoracic and abdominal cavity, but not substantially greater than that. | Reconstruction Field of View (0018,9317) |
| Reconstruction Protocol | Reconstruction Software | Shall be capable of performing reconstructions and producing images with all the parameters set as specified "Protocol Design Specification". |  |
| Image Header | Reconstruction Software | Shall record in the DICOM image header the actual values for the tags listed in the DICOM Tag column "Protocol Design Specification" as well as the model-specific Reconstruction Software parameters utilized to achieve conformance. |  |

## 3.4. Image QA

This activity involves evaluating the reconstructed images prior to image analysis. It includes image criteria that are necessary to reliably meet the Profile Claims.

### Discussion

This Image QA activity represents the portion of QA performed between image generation and analysis where characteristics of the content of the image are checked for conformance with the profile. The Image QA details listed here are the ones QIBA has chosen to highlight in relation to achieving the Profile claim. It is expected that sites will perform many other QA procedures as part of good imaging practices.

The Imaging Physician is identified here as ultimately responsible for this activity; however sites may find it beneficial for technologists to review these details at the time of imaging and identify cases which might require repeating acquisition and/or reconstruction to address issues with patient motion or artifacts.

Similarly, some or all of these checks may be performed at reporting time and as a result some or all of the lesion measurements may then be identified as not falling within the performance Claim of the Profile.

**Patient positioning** variation refers to differences in patient orientation (prone, supine, decubitus, etc.) and the use of positioning wedges. If the patient is supine at one encounter and prone at another, then the direction of gravity changes and some lesions may deform differently in a cavity, be compressed differently by other structures, or be affected by deformations of the organ in which they are sited.

**Scan Plane** variation refers to differences in gantry tilt or differences in head/neck positioning. Since several factors that affect quantitative assessment are not isotropic, changing the orientation of the lesion relative to the scan plane from one encounter to another can increase variability.

**Patient motion artifacts** can manifest in a variety of ways, such as a perceptible tram tracking appearance of the bronchioles or blurring of the lung architectural contours with lung windows.

**Dense object artifacts** (both internal and external to the patient) can variably degrade the ability to assess lesion contours as discussed in section 3.5, resulting in poor change measures and repeatability.

**Clinical conditions** can also degrade the ability to assess lesion contours, or influence the structure of the lesion itself. For example, atelectasis, pleural effusion, pneumonia and/or pneumothorax can result in architectural changes to the lung surrounding a nodule. Necrosis may complicate decisions on the lesion extent.

**Lesion Size** can affect the accuracy of measurements. Both theoretical considerations and the groundwork projects done by QIBA indicate that for lesions that are small, errors in measurement represent a greater percentage of the measured size. For lesions that are smaller than the limits defined in this profile, please see the profile produced by the QIBA Small Nodule group for more information on imaging recommendations and performance claims. For lesions that are extremely large, the limitations on measurement are based less on imaging physics and more on anatomy. Such lesions are likely to cross anatomical contours and abut structures that make consistent segmentation difficult.

**Contrast Enhancement** is required to be consistent between the two encounters. A non-contrast scan at both encounters satisfies that requirement.

**Lesion Measurability** is a general evaluation that is essentially left to the judgement of the Imaging Physician, and it is their responsibility to oversee segmentation and disqualify lesions with poor measurability or inconsistent segmentation between the two encounters. If the lesion has varying margin conspicuity on different slices, or is conspicuous but has complex geometry, or the segmentation software is visibly failing, or the background didn't respond to contrast the same way in the two encounters, the Imaging Physician should disqualify the lesion. Conversely, if the lesion is attached to another structure but the Imaging Physician is confident they can get consistent segmentation over the two encounters, they may allow a lesion that would be otherwise disqualified.

**Lesion Shape** is not explicitly identified as a specification parameter. No specific lesion shapes are considered a priori unsuitable for measurement. Although groundwork has shown that consistent measurements are more readily achieved with simple shapes than with complex shapes (such as spiculated lesions), the parameters for lesion size, lesion margin conspicuity and lesion measurability are felt to be sufficient. Moreover, complex shapes are even more difficult to assess accurately using simple linear measurements, increasing the relative added value of quantitative assessment.

Keep in mind that this Profile is “lesion-oriented”. If one lesion in a study is excluded from the Profile Claim because the lesion does not conform with the specifications in this section, that does not affect other lesions in the same study which do conform with these specifications at both encounters. Further, if a future study results in the excluded lesion being conformant at two encounters, then the claim holds across those two encounters.

While the Imaging Physician is responsible for confirming case conformance with the Image QA specifications, it is left to individual sites to determine the best approach in their work environment for capturing this audit data. Possible approaches include the use of a QIBA worksheet that captures this information, or asking the Imaging Physician to dictate each parameter into the clinical report (e.g. the scan is free of motion or dense object artifacts, contrast enhancement is consistent with baseline, the lesion margins are sufficiently conspicuous").

### Specification

The Imaging Physician shall ensure that the following specifications have been evaluated for each lesion being measured.

| **Parameter** | **Actor** | **Requirement** |
| --- | --- | --- |
| Patient Motion Artifacts | Imaging Physician | Shall confirm the images containing the lesion are free from artifact due to patient motion. |
| Dense Object Artifacts | Imaging Physician | Shall confirm the images containing the lesion are free from artifact due to dense objects, materials or anatomic positioning. |
| Clinical Conditions | Imaging Physician | Shall confirm that there are no clinical conditions affecting the measurability of the lesion. |
| Contrast Enhancement | Imaging Physician | Shall confirm that the phase of enhancement, if any, and degree of enhancement are consistent with baseline. |
| Patient Positioning Consistency | Imaging Physician | Shall confirm that any lesion deformation due to patient positioning is consistent with baseline (e.g. lesions may deform differently if the patient is supine in one scan and prone in another). |
| Breath Hold Consistency | Imaging Physician | Shall confirm that the breath hold state and degree of inspiration is consistent with baseline. |
| Scan Plane Consistency | Imaging Physician | Shall confirm that the anatomical slice orientation (due to gantry tilt or patient head/neck repositioning) is consistent with baseline. |
| Reconstructed Image Thickness | Imaging Physician | Shall confirm that the reconstructed image thickness is between 0.5mm and 2.5mm, and consistent with baseline (e.g. within 0.5mm). |
| Field of View | Imaging Physician | Shall confirm that the image field of view (FOV) resulting from acquisition and reconstruction settings appears consistent with baseline. |
| Lesion Measurability | Imaging Physician | Shall disqualify any lesion they feel might reasonably degrade the consistency and accuracy of the measurement.  Conversely, if artifacts or attachments are present but the Imaging Physician is confident and prepared to edit the contour to eliminate the impact, then the lesion need not be judged non-conformant to the Profile. |

## 3.5. Image Analysis

This activity involves quantitative assessment of vessel structure and tissue composition of atherosclerosis within a target vessel or vessel subtree. It includes criteria and procedures related to producing quantitative measurements from the images that are necessary to reliably meet the Profile Claims.

### Discussion

**Segmentation** may be performed automatically by a software algorithm, manually by a human reader, or semi-automatically by an algorithm with human guidance/intervention, for example to identify a starting seed point, stroke, or region, or to edit contours. Values may or may not correspond to the total of all the segmented voxels. The algorithm may consider partial volumes, do surface smoothing, lesion or organ modeling, or interpolation of user editing. The algorithm may also pre-process the images prior to segmentation. If a human reader participates in the segmentation, either by determining while looking at the images the proper settings for an automated process, or by manually editing contours, the settings for conversion of density into display levels (window and level) should either be fixed during the segmentation process or documented so that readers can apply consistent display settings at future encounters (or a different reader for the same encounter, if multiple readers may read each encounter, as for a clinical trial).

**Segmentation Object Storage** Storing segmentations and measurement results that can be loaded by an Image Analysis Tool analyzing data collected at a later date is certainly a useful practice as it can save time and cost. For this to happen reliably, the stored format must be compatible and the data must be stored and conveyed.

**Tool Version** Medical Devices such as the Image Analysis Tool are typically made up of multiple components (the hardware, the operating system, the application software, and various function libraries within those). Changes in any of the components can affect the behavior of the device. In this specification, the “device version” should reflect the total set of components and any changes to components should result in a change in the recorded device version. This device version may thus be different than the product release version that appears in manufacturer documentation.

**Lesion Marking** Determination of which lesions should be measured is out of scope for this Profile. Such determination may be specified within a protocol or specified by formal response criteria standards, or may be determined by clinical requirements. Lesions to be measured may be designated by the Imaging Physician at a clinical site, by a reader at a central reading facility, or they may be designated automatically by the software analysis tool.

**Audit Trail and Provenance** various details can be helpful when auditing the performance of the biomarker and the site using it. For example, it is helpful for the system to record the software version, set-up and configuration parameters used, or to be capable of recording the lesion segmentation contour as a DICOM Segmentation or NRRD file. Systems based on models should be capable of recording the model and parameters.

**Multiple Encounters** The Image Analysis Tool should be prepared to process both the current data and previous data at the same time and support matching across encounters in order to derive change values.

### Specification

Note: If the Imaging Physician has an Image Analyst prepare the measurement contours but the Imaging Physician still reviews and edits them, then the requirement is to validate the measurement performance of the Imaging Physician. If the Imaging Physician completely delegates performing the measurements to an Image Analyst, then requirement is to validate the measurement performance of the Image Analyst.

| **Parameter** | **Actor** | **Requirement** |
| --- | --- | --- |
| Vessel structure | Image Analysis Tool | When used by readers of average capability and having been trained on the tool, using phantom ground truth as outlined in the Assessment Procedures:   |  |  | | --- | --- | | **Lumen Area**, range X-Ymm2 | *Bias*: Zmm2 [l, h], *Intercept*: Wmm2 l, h], *Slope*: V [l, h], *Quadratic*: U [l, h] | | **Wall Area**, range X-Ymm2 | *Bias*: Zmm2 [l, h], *Intercept*: Wmm2 l, h], *Slope*: V [l, h], *Quadratic*: U [l, h] | | **Max Wall Thickness**, range X-Ymm | *Bias*: Zmm [l, h], *Intercept*: Wmm l, h], *Slope*: V [l, h], *Quadratic*: U [l, h] | | **Plaque Burden**, range X-Y (unitless) | *Bias*: Z [l, h], *Intercept*: W l, h], *Slope*: V [l, h], *Quadratic*: U [l, h] | |
| Tissue Composition | Image Analysis Tool | When used by readers of average capability and having been trained on the tool, using histology ground truth as outlined in the Assessment Procedures:   |  |  | | --- | --- | | **Calcified Area**, range X-Ymm2 | *Bias*: Zmm2 [l, h], *Intercept*: Wmm2 l, h], *Slope*: V [l, h], *Quadratic*: U [l, h] | | **LRNC Area**, range X-Ymm2 | *Bias*: Zmm2 [l, h], *Intercept*: Wmm2 l, h], *Slope*: V [l, h], *Quadratic*: U [l, h] | |
| Reader variability | Image Analysis Tool | When used by readers of average capability and having been trained on the tool, on clinical data sets as outlined in the Assessment Procedures:   |  |  | | --- | --- | | **Lumen Area**, range X-Ymm2 | *Inter-reader wSD*: Amm2 [l, h], *Intra-reader wSD*: Bmm2 [l, h] | | **Wall Area**, range X-Ymm2 | *Inter-reader wSD*: Amm2 [l, h], *Intra-reader wSD*: Bmm2 [l, h] | | **Max Wall Thickness**, range X-Ymm | *Inter-reader wSD*: Amm [l, h], *Intra-reader wSD*: Bmm [l, h] | | **Plaque Burden**, range X-Y (unitless) | *Inter-reader wSD*: A [l, h], *Intra-reader wSD*: B [l, h] | | **Calcified Area**, range X-Ymm2 | *Inter-reader wSD*: Amm2 [l, h], *Intra-reader wSD*: Bmm2 [l, h] | | **LRNC Area**, range X-Ymm2 | *Inter-reader wSD*: Amm2 [l, h], *Intra-reader wSD*: Bmm2 [l, h] | |
| Confidence interval | Image Analysis Tool | The Imaging Physician shall be able to call up a display for each measurand the range of plausible values for the given measurement stated in terms of the completed validation for the tool as a 95% interval. |
| Provenance records | Image Analysis Too | The identity, timing, and processing parameter settings for steps taken in the analysis of images shall be recorded and available to both visual as well as programmatic query. |
| Result  Verification | Imaging Physician | Shall review & approve margin contours produced by the tool. |
| Multiple Lesions | Image Analysis Tool | Shall allow multiple lesions to be measured.  Shall either correlate each measured lesion across encounters or support the Imaging Physician to unambiguously correlate them. |
| Multiple encounters | Imaging Physician | Shall re-process the first encounter if it was processed by a different Image Analysis Tool or Imaging Physician. |
| Multiple encounters | Image Analysis Tool | Shall be able to present the reader with both encounters side-by-side for comparison when processing the second encounter.  Shall be able to re-process the first encounter (e.g. if it was processed by a different Image Analysis Tool or Imaging Physician). |

# 4. Assessment Procedures

To conform to this Profile, participating staff and equipment (“Actors”) shall support each activity assigned to them in Table 3-1. Although most of the requirements described in Section 3 can be assessed for conformance by direct observation, some of the performance-oriented requirements cannot, in which case the requirement references an Assessment Procedure subsection here in Section 4.

## 4.1. Assessment Procedure: In-plane Spatial Resolution

This procedure can be used by a manufacturer or an imaging site to assess the In-plane Spatial Resolution of reconstructed images. Resolution is assessed in terms of the f50 value (in mm-1) of the modulation transfer function (MTF). Loosely speaking, the MTF represents the blur of an infinitely small feature of interest, f50 represents the spatial frequency at which the contrast of the feature has decreased by 50%, and the inverse of the f50 value represents the size of a feature that would be degraded 50%. So for an f50 value of 0.4 mm-1, features that are 2.5mm (or smaller) would have their contrast degraded by 50% (or more).

The assessor shall first warm up the scanner’s x-ray tube and perform calibration scans (often called air-calibration scans) according to scanner manufacturer recommendations.

The assessor shall scan a spatial resolution phantom, such as the ACR CT Accreditation Program (CTAP) Phantom’s module 1 or the AAPM TG233 phantom, which has a series of HU-value cylindrical inserts including one with soft-tissue equivalence. The acquisition protocol and reconstruction parameters shall conform to this Profile. The same protocol and parameters shall be used when performing the assessments in section 4.1 and 4.2, i.e., the noise level during resolution assessment should correspond to that measured during noise assessment.

The phantom shall be positioned with the center of the phantom at isocenter and properly aligned along the z-axis. For further details, refer to Section C, Step 3 of the CT Accreditation Testing Instructions:

http://www.acraccreditation.org/~/media/ACRAccreditation/Documents/CT/CT-Accreditation-Testing-Instructions.pdf

When the scan is performed, the assessor shall generate an MTF curve, measured as an average of the MTF in the x-y plane along the edge of a target soft-tissue equivalent insert using AAPM TG233 methodology as implemented in manufacturer analysis software, AAPM TG233 software or equivalent.

The assessor shall then determine and record the f50 value, defined as the spatial frequency (in mm-1 units) corresponding to 0.5 MTF on the MTF curve.

The assessor shall also generate the MTF curve and determine the f50 value using the edge of the "air insert" (i.e. an empty cutout in the phantom). If the phantom does not have a cutout that provides an air edge to assess, it is permitted to use the edge of the phantom.

The procedure described above is provided as a reference method. This reference method and the method used by the scanner manufacturer for FDA submission of MTF values are accepted methods for this assessment procedure. Note that for iterative reconstruction, the manufacturer may have specific test methodologies appropriate for the given algorithm.

Sites may submit to QIBA a proposed alternative method and evidence that the results produced by the proposed method are equivalent to this reference method or to the manufacturer method. Upon review and approval by QIBA, the alternative method will also become an accepted assessment procedure in this Profile.

This assessment procedure is applicable to conventional filtered backprojection and to iterative reconstruction.

Note that in addition to the x-y plane MTF, the AAPM TG233 phantom and software also provides an axial resolution measurement (MTF in the z-direction), which may be used as a confirmation of the axial resolution anticipated from the reconstructed image thickness.

## 4.2. Assessment Procedure: Voxel Noise

This procedure can be used by a manufacturer or an imaging site to assess the voxel noise of reconstructed images. Voxel noise is assessed in terms of the standard deviation of pixel values when imaging a material with uniform density.

The assessor shall first warm up the scanner’s x-ray tube and perform calibration scans (often called air-calibration scans) according to scanner manufacturer recommendations. The assessor shall then scan a phantom of uniform density, such as the ACR CT Accreditation Program (CTAP) Phantom’s module 3, which is a 20 cm diameter cylinder of water equivalent material. The phantom shall be placed at the isocenter of the scanner. The acquisition protocol and reconstruction parameters shall be conformant with this Profile. The same protocol and parameters shall be used when performing the assessments in section 4.1 and 4.2.

When the scan is performed, the assessor shall select a single representative slice from the uniformity portion of the phantom.

A region of interest (ROI) of at least 400 mm2 shall be placed near the center of the phantom. The assessor shall record the values reported for the ROI mean and standard deviation.

The assessor is encouraged to record and retain the images and associated measurement details but it is not required beyond the two values listed above. Such details can be helpful when the voxel noise is close to the acceptable limit.

Note that noise is assessed here in a standard sized object. In cases of protocols adaptive to the patient size (such as those using Automatic Exposure Control), the qualification of CT scanner noise should include noise as a function of size (using phantom such as that provisioned in AAPM TG233) if there is any concern that the noise performance may be outside compliance for different sizes.

The procedure described above is provided as a reference method. Sites may submit to QIBA a proposed alternative method (such as using the water phantom portion of a manufacturer’s QA phantom) and evidence that the results produced by the proposed method are equivalent to this reference method or manufacturer methodology. Upon review and approval by QIBA, the alternative method will also become an accepted assessment procedure in this Profile.

This assessment procedure is intended to be a simple phantom measurement that can be used to set a reasonable limit on the noise which is considered sufficient to avoid degrading segmentation performance. The procedure may be used for both conventional filtered backprojection and iterative reconstruction methods. It is noted that when characterizing reconstruction methods, voxel noise is a limited representation of image noise when noise texture is varied.

## 4.3. Assessment Procedure: Vessel structure Bias and Linearity

This procedure can be used by a manufacturer or an imaging site to assess the bias and linearity of vessel structure. The bias and linearity of vessel structure calculations is estimated using a set of phantoms where ground truth measurements assessed by micrometer are known. The phantoms must be fabricated according to specifications that mimic appropriate CT characteristics and in sizes that represented a range of vessel sizes and presentations of interest. The phantoms must be filled with contrast media utilized in practice and scanned in a range of scanner settings that is representative of current clinical practice but which meet the requirements of this Profile. Statistical measures of bias were estimated from these data.

### Obtain test image set

The test image set consists of scanned physical phantoms (Figure 1).



Figure 1: Physical Dimensions of Vascular Phantoms

An example material is Noryl, which has a density of 1.06 g/ml. The specifications for the phantoms that must be used are displayed on Table 1. If a given manufacturer wishes to support a subset rather than the whole range, then a note regarding the reduced scope needs to be made explicitly when representing conformance.

Table 1. Phantom Specifications

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **A** |  | **B** |  | **C** |  |  | **D** | **E** | **F** | **G** |
| **Phantom number** | **Surrogate artery** | **Reference diameter (mm)** | **Reference area (mm^2)** | **Stenosis diameter (mm)** | **Stenosis area (mm^2)** | **Stenosis length (mm)** | **Diameter stenosis (%)** | **Area stenosis (%)** | **Tube length1 (mm)** | **Tube thick1**  **(mm)** | **Tube**  **length2**  **(mm)** | **Tube**  **thick2**  **(mm)** |
| 1 | coronary | 2.0 | 3.1 | 0.7 | 0.4 | 10.0 | 65.0 | 87.8 | 40.0 | 1.0 | 80.0 | 1.0 |
| 2 | coronary | 4.0 | 12.6 | 1.3 | 1.3 | 10.0 | 67.5 | 89.4 | 40.0 | 1.0 | 80.0 | 1.0 |
| 3 | coronary/  vertebral | 4.0 | 12.6 | 2.7 | 5.7 | 10.0 | 32.5 | 54.4 | 40.0 | 1.0 | 80.0 | 1.0 |
| 4 | carotid | 6.0 | 28.3 | 2.0 | 3.1 | 10.0 | 66.7 | 88.9 | 40.0 | 1.0 | 80.0 | 1.0 |
| 5 | carotid | 6.0 | 28.3 | 3.0 | 7.1 | 20.0 | 50.0 | 75.0 | 80.0 | 1.0 | 60.0 | 1.0 |
| 6 | carotid | 6.0 | 28.3 | 4.0 | 12.6 | 20.0 | 33.3 | 55.6 | 80.0 | 1.0 | 60.0 | 1.0 |
| 7 | femoral | 9.0 | 63.6 | 3.0 | 7.1 | 20.0 | 66.7 | 88.9 | 80.0 | 1.0 | 60.0 | 1.5 |
| 8 | femoral | 9.0 | 63.6 | 6.0 | 28.3 | 20.0 | 33.3 | 55.6 | 80.0 | 1.0 | 60.0 | 1.5 |
| 9 | aorta | 20.0 | 314.2 | 7.0 | 38.5 | 40.0 | 65.0 | 87.8 | 160.0 | 2.0 | 20.0 | 1.5 |

Each tube is a surrogate for at least one blood vessel. Phantom 1, 2, and 3 represent the size range of coronary arteries. Phantom 3 represents coronary and vertebral arteries. Phantom 4, 5, and 6 represent carotid arteries. Phantom 7 and 8 represent femoral arteries. Phantom 9 represents the abdominal aorta.

For the scans, the phantoms must be filled with diluted contrast agent (Omnipaque) between 10-12 mg Iodine /ml to achieve the same contrast between vessel wall and lumen found in patient CTA scans at 100-120 kVp (based on published relationship of iodine concentration vs. HU for 80-120 kVp, ref. [[14](#_ENREF_14)].

Suspend the phantoms in a plastic cage submerged in a box of vegetable oil, and scan at the same time. Acquire the test image set according to the requirements of this Profile (e.g. patient handling, acquisition protocol, reconstruction), to minimally include four admissible variations of scan parameters. By using a variance in CT scanning parameters, the performance analysis evaluates a spectrum of images rather than only one.

### Determine Measurands

Import the DICOM files into the analysis software and perform the analysis, recording how requirements as described in the Image Analysis Activity have been met.

The assessor is permitted to edit the segmentation or seed point if that is part of the normal operation of the tool. If segmentation edits are performed, results should explicitly indicate whether they were achieved with and without editing.

When evaluating an Image Analysis Tool, at least two reader shall be used for this assessment procedure.

When evaluating an Imaging Physician, it is acceptable to use a single tool for the assessment procedure.

The assessor shall calculate the measurands (Y) of each cross section (denoted Y*i*) where Y denotes the measurand, and *i* denotes the *i*-th target.

### Calculate statistical metrics of performance

The natural log of the true measurements (Xi) as assessed by micrometer of each cross section are known and are provided in the dataset.

The assessor shall calculate the individual percentage bias (*bi*) of the measurement of each cross section as

The assessor shall estimate the population bias over the N cross sections as

The assessor shall convert to a percentage bias estimate as

=

The assessor shall fit an ordinary least squares (OLS) regression of the on and shall estimate the slope ), intercept, and quadratic term.

The assessor shall divide the targets into a small vessel subgroup (vessels <4.5 mm) and a large subgroup (vessels >= 4.5 mm). The assessor shall repeat the percentage population bias calculation on each subgroup to estimate subgroup percentage bias, and then assess the ability to pool the results.

The assessor is recommended to also plot the measurand estimate ( versus ) and the OLS regression curve of the estimates as part of the assessment record.

## 4.4. Assessment Procedure: Tissue Characteristics Bias and Linearity

This procedure can be used by a manufacturer the bias and linearity of tissue characteristics using histopathology as ground truth. Since annotation and positioning steps are performed with some degree of subjectivity, bias and linearity were estimated based on a random sample of pathologists and a random sample of radiologist/positioner combinations.

### Obtain test image set

Perform histology processing and assessment only at accredited centers and to ensure that ground truth processing be blinded to all other study data. Process sections at 2.0 mm throughout the length of the tissue specimen. It is acceptable to exclude sections (within reason and in no event cherry picking desirable sections) when the sample is too distorted, if it is missing significant portions due to specimen processing, if there is not enough visible tissue characteristics or distinct morphology to orient the *ex vivo* histology image to the *in vivo* radiology imaging, or if the pathologist marked tissue as a mixture of tissue types.

Correlate histology cross-sections with locations in the CT image volume. In one acceptable method, tissue portions of histopathologic images are converted into a mesh to facilitate returning its shape to its *in vivo* original using a finite element method (FEM) that factors in the tissue material type to simulate the stretching/compression of the relatively elastic material and then allow a positioner to rotate, tilt, and move the histology cross-section in 3D to provide a plausible alignment between the histopathology and radiology presentation. It is important to note that the matching must be performed using only raw CT, scrupulously avoiding use of the image analysis tool’s computed segmentations to preserve objectivity in the matching.

Subjectivity of 3D placement must be systematically mitigated with consideration due to the sources of potential misalignment: (a) longitudinal displacement up or down the length of the vessel, (b) the angular tilt of the plane away from perpendicular to the vessel, and (c) the angular spin about the vessel.

### Determine Measurands

Import the DICOM files into the analysis software and perform the analysis, recording how requirements as described in the Image Analysis Activity have been met.

The assessor is permitted to edit the segmentation or seed point if that is part of the normal operation of the tool. If segmentation edits are performed, results should explicitly indicate whether they were achieved with and without editing.

When evaluating an Image Analysis Tool, a single reader shall be used for this entire assessment procedure.

When evaluating an Imaging Physician, a single tool shall be used for this entire assessment procedure.

The assessor shall calculate the measurands (Y) of each cross section (denoted Y*i*) where Y denotes the measurand, and *i* denotes the *i*-th target.

### Calculate statistical metrics of performance

The following must be performed in a strictly held-out set of subjects, and cannot be done iteratively. One the hold-out set has been used for evaluation, it may not be used for a later evaluation after the software changes, accept insofar as regression tests are performed where there is no material algorithm changes. It is highly advisable to anticipate this in advance when data is collected, and to pre-identify cohorts, and with sufficient numbers collected to support potentially many year development programs.

In order to properly account for sources of subjectivity, a minimum of three independent pathologist annotations and four positioned-radiologist reader combinations (that is, two independent positioning crossed with two independent radiology readings at each respective position) shall be collected and included in the analysis.

To assess bias, plot the value calculated by histopathologic examination versus the value calculated by image analysis tool. Inspect the resulting plot for associations between the magnitude of the histopathologic measurement and bias, associations between the magnitude of the histopathologic measurements and heteroscedasticity in the image analysis tool measurements, and limits of quantitation of image analysis tool measurements.

Fit a linear model, where the dependent variable is the image analysis tool measurement (Y) and the independent variable is the histopathology value (X). Generalized estimating equations (to account for the fact that subjects have more than one target) may be used to estimate the linear function, as follows: E(Y|X) = β0 + β1X. An exchangeable working covariance may be used. Construct a 95% CI for the intercept  from the fitted model. CIs not containing 0 indicate constant bias. Also construct a 95% CI for the slope, intercept, and quadratic term. These calculations allow conclusions to be drawn regarding the linearity of the measurements (32).

Estimate the precision of the image analysis tool measurements by the standard deviation:

, where  is the sample mean of the differences, .

Construct a 95% CI for the standard deviation using bootstrap methods.

Present the bias profile (bias of measurements for various ranges of histopathology values versus the histopathology value) and precision profile (standard deviation of image analysis tool measurements from subjects with similar histopathologic values versus the histopathologic value) as summaries of image analysis tool measurement performance for the bias and precision components, respectively. Report the coverage probability at 80% coverage. The coverage probability coverage probability is the probability that the absolute difference between the value calculated by image analysis tool measurements and the value calculated by histology is less than d0, ie, π = Pr(|Y − X| < d0). Plot the coverage probability for a range of values for d0.

## 4.5. Assessment Procedure: Reader / Image Analysis Tool Variability

<fill in>

# Appendices

## Appendix A: Acknowledgements and Attributions

This document is proffered by the Radiological Society of North America (RSNA) Quantitative Imaging Biomarker Alliance (QIBA) Atherosclerosis Biomarkers Biomarker Committee. The committee is composed of representatives from academia, professional societies, imaging device manufacturers, image analysis image analysis tool developers, image analysis laboratories, biopharmaceutical industry, government research organizations, and regulatory agencies, among others. All work is classified as pre-competitive.

A more detailed description of the committee and its work can be found at the following web link: <http://qibawiki.rsna.org/index.php?title=Committees>.

QIBA Atherosclerosis Biomarkers Committee Profile Co-Authors:

|  |  |
| --- | --- |
| Buckler, Andrew J. MS | Elucid Bioimaging Inc. |
| DeMarco, James Kevin MD | Walter Reed |
| Dey, Damini PhD | Cedars-Sinai / UCLA |
| Duguay, Taylor BS | Medical University of South Carolina | MUSC |
| Ferencik, Maros MD, PhD | Oregon Health & Science University (OHSU) |
| Jimenez-Juan, Laura MD | University of Toronto, Canada |
| Kitslaar, Pieter MSc | Medis Cardiovascular Imaging |
| Kolossváry, Márton | Semmelweis University (Budapest, Hungary) |
| Maurovich-Horvat, Pál MD, PhD, MPH, FSCCT, FESC | Semmelweis University (Budapest, Hungary) |
| Moody, Alan MBBS, FRCP, FRCR | London Health Sciences Centre (Canada) |
| Obuchowski, Nancy PhD | Cleveland Clinic Foundation |
| Paul, Narinder MD, MRCP, FRCR, FRCRC | London Health Sciences Centre (Canada) |
| Richards, T BS | Duke University |
| Rinehart, Sarah MD | Piedmont Atlanta Hospital |
| Saba, Luca MD | University of Cagliari (Italy) |
| Samei Ehsan, PhD | Duke University |
| Schoepf, Uwe Joseph MD | Medical University of South Carolina |
| St. Pierre, Samantha BS | Elucid Bioimaging Inc. |
| van Assen, Marly Msc | Medical University of South Carolina |
| Varga-Szemes, Akos MD, PhD | Medical University of South Carolina |
| Virmani Renu, MD | CV Path Institute |

QIBA Atherosclerosis Biomarkers Committee Profile Contributors:

|  |  |
| --- | --- |
| Cademartiri , Filippo MD, PhD | SDN IRCCS, Naples, Italy |
| Douglas, Pamela MD | Duke |
| Ferguson, Terry James MD | Amgen |
| Guimaraes, Alexander MD, PhD | Oregon Health & Science University |
| Gupta, Ajay MD | Weill Cornell Medical College |
| Hanneman, Kate MD | University Health Network, Canada |
| Hedin, Ulf MD, PhD | Karolinska Institute |
| Hoelzer, Philipp PhD | Siemens AG Healthcare (Germany) |
| Hoffman, Udo MD | Massachusetts General Hospital (MGH) |
| Jackson, Edward F. PhD | University of Wisconsin, School of Medicine & Public Health |
| Jarecha, Rudresh MBBS, DMRE, DNB | PAREXEL International |
| Khan, Amir PhD | University of Maryland Medical Center (UMMC) |
| Krams, Robert MD, PhD | Imperial College London |
| Lal, Brajesh MD | University of Maryland Medical Center (UMMC) |
| Narula, Jagat MD, DM, PhD, MACC, FAHA, FRCP | Mt. Sinai School of Medicine |
| O'Donnell, Kevin MASc | Canon Medical Research USA |
| Perlman, Eric S. MD | Perlman Advisory Group, LLC |
| Richards, Toby MD, FRCS | University College London (UCL) |
| Rossi, Alexia MD, PhD | Erasmus / Circle Cardiovascular |
| Siegelman, Jenifer MD, MPH | Takeda Pharmaceuticals |
| Sullivan, Daniel C. MD | Duke University |
| Wintermark, Max MD, MAS, MBA | Stanford University Medical Center |

The Atherosclerosis Biomarkers Committee is deeply grateful for the support and technical assistance provided by the staff of the Radiological Society of North America.

# 

## Appendix B: Conventions and Definitions

Acquisition vs. Analysis vs. Interpretation: This document organizes acquisition, reconstruction, post-processing, analysis and interpretation as steps in a pipeline that transforms data to information to knowledge. Acquisition, reconstruction and post-processing are considered to address the collection and structuring of new data from the subject. Analysis is primarily considered to be computational steps that transform the data into information, extracting important values. Interpretation is primarily considered to be judgment that transforms the information into knowledge. (The transformation of knowledge into wisdom is beyond the scope of this document.)

Image Analysis, Image Review, and/or Read: Procedures and processes that culminate in the generation of imaging outcome measures, such lesion response criteria. Reviews can be performed for eligibility, safety or efficacy. The review paradigm may be context specific and dependent on the specific aims of a trial, the imaging technologies in play, and the stage of drug development, among other parameters.

Image Header: that part of the image file (or dataset containing the image) other than the pixel data itself.

Imaging Phantoms: devices used for periodic testing and standardization of image acquisition. This testing must be site specific and equipment specific and conducted prior to the beginning of a trial (baseline), periodically during the trial and at the end of the trial.

Encounter: a discrete period during the course of a clinical trial when groups of imaging exams or clinical exams are scheduled.

Lesion Definition Variability: the clarity of the lesion contour in the images. It originates from the biological characteristics of the lesion, technical characteristics of the imaging process, and perhaps on the perception, expertise and education of the operator.

Technical Variability - originates only from the ability to drawing unequivocal objects. In other words, the perception of lesion definition is supposed absolutely clear and similar for any given operator when attempting to assess “Technical” variability.

Global Variability - partitioned as the variability in the lesion definition plus the “Technical” variability.

Intra-Reader Variability - is the variability in the interpretation of a set of images by the same reader after an adequate period of time inserted to reduce recall bias.

Inter-Reader Variability - is the variability in the interpretation of a set of images by the different readers.

Repeatability – considers multiple measurements taken under the same conditions (same equipment, parameters, reader, algorithm, etc.) but different subjects.

Reproducibility – considers multiple measurements taken where one or more conditions have changed.

## Appendix C: Imaging Resolution Details

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Vessel** | **Resolution (mm)** | | **Healthy**  **(Axial)** | | **Healthy**  **(Coronal/Sagittal)** | | | **Diseased**  **(Axial)** | | **Disease**  **(Coronal/Sagittal)** |
| **FEMORAL** | | | | | | | | | | |
| **CT Axial Orientation Scan** | | | | | | | | | | |
| Common Femoral Artery1,2 | 0.5 x 0.5 x 0.63 | Lumen Diameter = 9.5 mm  Wall Thickness = 1.42 mm | |  | | | Lumen Diameter = 9.02 mm  Wall Thickness = 1.66 mm | |  | |
| Superficial Femoral Artery3,4 | 0.5 x 0.5 x 0.63 | Lumen Diameter = 7 mm  Wall Thickness = 1.27 mm | |  | | | Lumen Diameter = 5.28 mm  Wall Thickness = 2.13 mm | |  | |
| Deep Femoral Artery (profunda)8 | 0.5 x 0.5 x 0.63 | Lumen Diameter = 6.8 mm  Wall Thickness = 1.2 mm | |  | | | Lumen Diameter = 5.2 mm  Wall Thickness = 2 mm | |  | |
| **CAROTID** | | | | | | | | | | |
| **CT Axial Orientation Scan** | | | | | | | | | | |
| Common Carotid Artery1,9 | 0.5 x 0.5 x 0.63 | Lumen Diameter = 6.3 mm  Wall Thickness = 0.8 mm | |  | | | Lumen Diameter = 3.02 mm  Wall Thickness = 2.44 mm | |  | |
| External Carotid Artery9 | 0.5 x 0.5 x 0.63 | Lumen Diameter = 3.5 mm  Wall Thickness = 1.1 mm | |  | | | Lumen Diameter = 2.3 mm  Wall Thickness = 1.7 mm | |  | |
| Internal Carotid Artery5,9 | 0.5 x 0.5 x 0.63 | Lumen Diameter = 5.5 mm  Wall Thickness = 1.3 mm | |  | | | Lumen Diameter = 3.3 mm  Wall Thickness =2.4 mm | |  | |
| **CORONARY** | | | | | | | | | | |
| **CT Varied Orientation** | | | | | | | | | | |
| Proximal RCA6,7 | 0.5 x 0.5 x 1.25 | Lumen Diameter = 3.4 mm  Wall Thickness = 1.2 mm | | | |  | Lumen Diameter = 1.4 mm  Wall Thickness = 2.2 mm | |  | |
| Mid RCA6,7 | 0.5 x 0.5 x 1.25 | Lumen Diameter = 3.5 mm  Wall Thickness = 1.1 mm | | | |  | Lumen Diameter = 1.3 mm  Wall Thickness = 2.2 mm | |  | |
| Distal RCA6,7 | 0.5 x 0.5 x 1.25 | Lumen Diameter = 2.1 mm  Wall Thickness = 1.0 mm | | | |  | Lumen Diameter = 1.3 mm  Wall Thickness = 1.8 mm | |  | |
| Left Main Coronary Artery6,7 | 0.5 x 0.5 x 1.25 | Lumen Diameter = 4.5 mm  Wall Thickness = 1.85 mm | | | |  | Lumen Diameter = 2.8 mm  Wall Thickness = 2.7 mm | |  | |
| Proximal LAD Branch of LCA6,7 | 0.5 x 0.5 x 1.25 | Lumen Diameter = 3.9 mm  Wall Thickness = 1.0 mm | | | |  | Lumen Diameter = 3.0 mm  Wall Thickness = 2.0 mm | |  | |
| Mid LAD Branch of LCA6,7 | 0.5 x 0.5 x 1.25 | Lumen Diameter = 2.5 mm  Wall Thickness = 1.0 mm | | | |  | Lumen Diameter = 2.0 mm  Wall Thickness = 2.0 mm | |  | |
| Distal LAD Branch of LCA6,7 | 0.5 x 0.5 x 1.25 | Lumen Diameter = 1.85 mm  Wall Thickness = 0.79 mm | | | |  | Lumen Diameter = 1.85 mm  Wall Thickness = 2.0 mm | |  | |
| Proximal Circumflex Branch of LCA6,7 | 0.5 x 0.5 x 1.25 | Lumen Diameter = 3.8 mm  Wall Thickness = 0.42 mm | | | |  | Lumen Diameter = 2.0 mm  Wall Thickness = 2.0 mm | |  | |
| Mid Circumflex Branch of LCA6,7 | 0.5 x 0.5 x 1.25 | Lumen Diameter = 2.8 mm  Wall Thickness = 0.42 mm | | | |  | Lumen Diameter = 2.0 mm  Wall Thickness = 2.0 mm | |  | |
| Distal Circumflex Branch of LCA6,7 | 0.5 x 0.5 x 1.25 | Lumen Diameter = 2.4 mm  Wall Thickness = 0.42 mm | | | |  | Lumen Diameter = 2.0 mm  Wall Thickness = 2.0 mm | |  | |

1 Lumen diameter measurements taken from[[15](#_ENREF_15)]

2 Wall thickness measurements taken from [[16](#_ENREF_16)]

3 Lumen diameter measurements taken from [[17](#_ENREF_17)]

4 Wall thickness measurements taken from [[18](#_ENREF_18)]

5Lumen diameter measurements taken from [[19](#_ENREF_19)]

6Lumen diameter measurements taken from [[20](#_ENREF_20)]

7Wall thickness measurements taken from [[21-23](#_ENREF_21)]

8Estimated

9Measurements taken from review of typical images

## Appendix D: Measurands with Description and Units

|  |  |  |
| --- | --- | --- |
| Measurand | Description | Units |
| Max Wall Thickness | Calculated by measuring the maximum cross-sectional wall thickness (“Max” refers to the maximum thickness of each cross section given that the wall thickness is not uniform) | Expressed in units of mm |
| Lumen Area | Calculated as cross-sectional area of blood channel at position along vessel centerline | Expressed in units of mm2 |
| Wall Area | Calculated as cross-sectional area of vessel at position along vessel centerline minus the LumenArea at that position | Expressed in units of mm2 |
| Plaque Burden | Calculated as WallArea / (WallArea + LumenArea) | Expressed as a unitless ratio |
| LRNC Area | The pathologic retention of lipids, particularly lipoproteins, by intimal/medial cells leading to progressive cell loss, cell death, degeneration, and necrosis. It is a mixture of lipid, cellular debris, blood and water in various concentrations. | Expressed in units of mm2 |
| Calcified Area | The physiologic defensive biological process of attempting to stabilize plaque, which has a mechanism akin to bone formation. | Expressed in units of mm2 |

## Appendix E: CT Angiography Signal Applicability and Published Performance

The ability of standard CTA to reliably identify atherosclerotic plaque tissue characteristics and correlate them with cardiovascular events relative to the more widely reported use of MRI has not previously been well established in the literature. In principle, the Hounsfield Unit scale used by CT has the potential to be more quantitative than MRI due to the objective basis on which the voxel values are based, but terms like “soft plaque” instead of more specific terms like lipid-rich necrotic core are sometimes used in literature [[24](#_ENREF_24)], suggesting less specificity. Ideal image processing would take this factor and partial volume effects into account. The speed and high-resolution of standard CTA scan protocols brings promise of more widespread adoption.

Examination of arterial beds using radiological imaging is common among three image modalities: ultrasound, CT, and MRI. A particularly thorough review paper [[25](#_ENREF_25)] investigated the use of noninvasive imaging techniques in identifying plaque components and morphologic characteristics associated with atherosclerotic plaque vulnerability in carotid and coronary arteries. The review found 62 studies: 23 of which investigated ultrasound, 18 CT, 18 MRI, 2 that investigated both CT and ultrasound, and 1 that investigated both MRI and ultrasound. The 50 studies on the carotid arteries used histology as reference method, while the 12 studies on the coronary arteries used IVUS (but this would not be considered definitive as IVUS is itself not validated by histology).

### Vessel Structure

| *Source* | *Imaging Method* | *Reference* | | *object* | *Structure measurement* | *Offset* | *Variability* |
| --- | --- | --- | --- | --- | --- | --- | --- |
| de Weert 2006 [[26](#_ENREF_26)] | CT | Inter-observer | | 7 Human carotid | Plaque Area (mm2) | -5% constant over 74-111 mm2 range; poor below | 8% constant over 74-111 mm2 range; poor below |
| de Weert 2006 [[26](#_ENREF_26)] | CT | Inter-observer | | 13 Human carotid | Lumen Area (mm2) | 0% constant over 22-63 mm2 range; poor below | 1% constant over 22-63 mm2 range; poor below |
| Kwee 2009 [[27](#_ENREF_27)] | CT Auto | 1.5T MR | | 14 Human carotid | Lumen Area | 9% constant over 19-72 mm2 range; poor below | 37% % constant over 19-72 mm2 range; poor below |
| Obaid 2013 [[28](#_ENREF_28)] | CT | Intra-observer | 22 Human coronaries | | Lumen Area (mm2) | -1% constant over 352-468 mm2 range; poor below | 4% constant over 352-468 mm2 range; poor below |
| Papadopoulou 2013 [[29](#_ENREF_29)] | CT | Intra-observer | 162 Human coronaries | | Lumen Area (mm2) | 2% constant over 12.8-23.2 mm2 range; poor below | 10% constant over 12.8-23.2 mm2 range; poor below |
| Papadopoulou 2013 [[29](#_ENREF_29)] | CT | Intra-observer | 535 Human coronaries | | Vessel Area (mm2) | -1% | 7% |
| Papadopoulou 2012 [[30](#_ENREF_30)] | CT | Intra-observer | 435 Human coronaries | | Plaque Area (mm2) | 1% constant over 6.1-16.4 mm2 range; poor above | 14% constant over 6.1-16.4 mm2 range; poor above |
| Rinehart 2011 [[31](#_ENREF_31)] | CT | Inter-observer | 85 Human coronaries | | Minimum Lumen Diameter (mm) | -2% constant over 1.7-4.4 mm range; poor below | 8% constant over 1.7-4.44 mm range; poor below |
| Rinehart 2011 [[31](#_ENREF_31)] | CT | Inter-observer | 179 Human coronaries | | Minimum Lumen Area (mm2) | 0% constant over 1.6-21.2 mm2 range; poor below | 14% constant over 1.6-21.2 mm2 range; poor below |

### Tissue Composition

With a specific focus on CT, we quote a small illustrative sampling here to indicating the nature and utility of CT for characterizing atherosclerotic plaque:

* (quoted directly from introduction in [[32](#_ENREF_32)]) In view of the limitations of [digital subtraction angiography], there is an increasing interest in CTA as a modality for assessing the carotid artery bifurcation. Computed tomography angiography is an imaging modality that can be used to accurately visualize the severity of luminal stenosis in 3D. With CTA it is extremely easy to detect calcifications in the carotid artery. CTA has also become an established method for successful artery calcium scoring in coronary arteries. With the introduction of Multi-detector CT (MDCT) in 1998 fast imaging at high temporal and spatial resolution became possible. The main advantage of this technology compared with conventional mechanical spiral CT scanner is that it consists of multiple detector rows, which allow simultaneous acquisition of multiple slices. CT scanners using e.g. 16 and 64 – slice technology offer a very high spatial resolution and can generate very thin slices allowing the acquisition of isotropic voxels. It has been shown, using 16-slice CT, that non-calcified coronary lesions could be detected with a reasonable sensitivity of 78%. It has been also shown, with comparison to histology, that assessment of carotid atherosclerotic plaque components is feasible with MDCT using different plaque components Hounsfield units (HU) densities in vitro [20] and in vivo [21]. In Figure 1.3 an illustration from of atherosclerotic plaques in MDCT cross-sectional slices and corresponding histology samples are shown.
* (quoted directly from conclusions in [[26](#_ENREF_26)]) The present study shows that MDCT is capable of characterizing and quantifying plaque burden, calcifications, and fibrous tissue in atherosclerotic carotid plaque in good correlation with histology, and that lipid core can be adequately quantified in mildly calcified plaques. Furthermore the MDCT-based assessment of atherosclerotic plaque component quantities was possible with moderate observer variability.
* (quoted directly from conclusions in [[33](#_ENREF_33)]) Our study results indicate that [dual-source computed tomography] angiography of the carotid arteries is feasible and the evaluation of carotid tissue characteristics allows non-invasive assessment of different plaque components. Although some limitations remain, [dual-source computed tomography] offers a high potential to non-invasively assess the patients at a higher risk for stroke.

An often cited study supporting the use of CT to characterize plaques, while also documenting the factors which can complicate overly simplistic methods [[34](#_ENREF_34)], states:

* (from discussion) This study provides proof of principle that the tissue characteristics of atherosclerotic plaques determined by CTA accurately reflects tissue characteristics of the lesion as defined by histologic examination.
* (from results) The mean CT Hounsfield attenuation was measured for each of the 2x2-mm squares that were electronically drawn on the CT reformatted images and considered in the linear regression model with respect to the percentages of connective tissue, lipid-rich necrotic core, hemorrhage, and calcifications in the corresponding histologic and micro-CT squares. The results of the linear mixed model (i.e., mean Hounsfield attenuation for each histologic component and the 95% confidence intervals for these densities) are displayed in Table 2. There was significant overlap in CT Hounsfield densities between lipid-rich necrotic core and connective tissue. There was also some overlap between connective tissue and hemorrhage. Cutoff densities between lipid-rich necrotic core and connective tissue, connective tissue and hemorrhage, and hemorrhage and calcifications were determined as the halfway Hounsfield attenuation between the average densities for each of the components: 39.5 Hounsfield units (HU) between lipid-rich necrotic core and connective tissue, 72.0 HU between connective tissue and hemorrhage, and 177.1 HU between hemorrhage and calcifications.

Table 2 here reproduced for convenience (and with permission):



Wintermark’s Table 2, de Weert’s result regarding cutoff values [[26](#_ENREF_26)], and also work by Sieren [[35](#_ENREF_35)] in lung tissues considered for purposes of establishing the basic relationships between tissue types and their HU values generally provide points of comparison with our work. These reference works highlight both what is good about using HUs for characterization of lesion characteristics but at the same that which makes it challenging. The principal challenge to QIBA-conformant image analysis tool is to mitigate limitations gleaned from the various studies.

More recently [[36](#_ENREF_36)]:

1. Tissue characteristics implicated in high risk atherosclerotic plaque may be quantitatively measured from routinely available CTA in high correlation with histopathology (with Pearson correlation coefficients for measurements greater than 5mm2 of 0.973, 0.856, and 0.885 for Calcification, LRNC, and Matrix respectively) and low reader variability (with Repeatability Coefficients ≤ 1.8 mm2 and Reproducibility Coefficients ≤ 4.4 mm2), assessed on 2D cross-sections within calculated 3D volumes.
2. Overestimation of calcification on CTA may be successfully mitigated as evidenced by bias in measurements of calcification area being -0.096 mm2 and demonstrating the property of linearity as confirmed by histopathology when evaluated on held-out test data.
3. Underestimation of lipid-rich necrotic core (LRNC) on CTA may be successfully mitigated as evidenced by bias in measurements of LRNC area being 1.26 mm2 and demonstrating the property of linearity as confirmed by histopathology when evaluated on held-out test data.
4. Bias in measurements of tissue matrix area on CTA was -2.44 mm2 and demonstrating the property of linearity as confirmed by histopathology when evaluated on held-out test data.

## References

1. Maroules, C.D., et al., *Coronary artery disease reporting and data system (CAD-RADSTM): inter-observer agreement for assessment categories and modifiers.* Journal of cardiovascular computed tomography, 2018. **12**(2): p. 125-130.

2. Nadjiri, J., et al., *Incremental prognostic value of quantitative plaque assessment in coronary CT angiography during 5 years of follow up.* Journal of cardiovascular computed tomography, 2016. **10**(2): p. 97-104.

3. Ciccone, M.M., et al., *Cardiovascular risk evaluation and prevalence of silent myocardial ischemia in subjects with asymptomatic carotid artery disease.* Vasc Health Risk Manag, 2011. **7**: p. 129-34.

4. Steinvil, A., et al., *Impact of Carotid Atherosclerosis on the Risk of Adverse Cardiac Events in Patients With and Without Coronary Disease.* Stroke, 2014. **45**(8): p. 2311-2317.

5. Polak, J.F., et al., *Carotid artery plaque and progression of coronary artery calcium: the multi-ethnic study of atherosclerosis.* J Am Soc Echocardiogr, 2013. **26**(5): p. 548-55.

6. Insull, W., *The pathology of atherosclerosis: plaque development and plaque responses to medical treatment.* Am J Med, 2009. **122**(1 Suppl): p. S3-S14.

7. Schaar, J.A., et al., *Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece.* Eur Heart J, 2004. **25**(12): p. 1077-82.

8. Ibrahimi, P., et al., *Coronary and carotid atherosclerosis: How useful is the imaging?* Atherosclerosis. **231**(2): p. 323-333.

9. Sigala, F., et al., *Coronary versus carotid artery plaques. Similarities and differences regarding biomarkers morphology and prognosis.* Curr Opin Pharmacol, 2018. **39**: p. 9-18.

10. Carter, H.H., et al., *Evidence for Shear Stress-Mediated Dilation of the Internal Carotid Artery in Humans.* Hypertension, 2016. **68**(5): p. 1217-1224.

11. Davies, J.R., et al., *Radionuclide Imaging for the Detection of Inflammation in Vulnerable Plaques.* J Am Coll Cardiol, 2006. **47**(8, Supplement): p. C57-C68.

12. Chatzizisis, Y.S., et al., *Association of global and local low endothelial shear stress with high-risk plaque using intracoronary 3D optical coherence tomography: Introduction of 'shear stress score'.* Eur Heart J Cardiovasc Imaging, 2017. **18**(8): p. 888-897.

13. Gnasso, A., et al., *In vivo association between low wall shear stress and plaque in subjects with asymmetrical carotid atherosclerosis.* Stroke, 1997. **28**(5): p. 993-8.

14. Bae, K.T., *Intravenous contrast medium administration and scan timing at CT: considerations and approaches.* Radiology, 2010. **256**(1): p. 32-61.

15. Raninen, R., et al., *Arterial wall thickness measurements by B mode ultrasonography in patients with Takayasu's arteritis.* Annals of the rheumatic diseases, 1996. **55**(7): p. 461-465.

16. Sandgren, T., et al., *The diameter of the common femoral artery in healthy human: influence of sex, age, and body size.* Journal of vascular surgery, 1999. **29**(3): p. 503-510.

17. Beach, K.W., et al., *An ultrasonic measurement of superficial femoral artery wall thickness.* Ultrasound in Medicine and Biology, 1989. **15**(8): p. 723-728.

18. Ohana, M., et al., *Detailed cross-sectional study of 60 superficial femoral artery occlusions: morphological quantitative analysis can lead to a new classification.* Cardiovascular diagnosis and therapy, 2014. **4**(2): p. 71.

19. Krejza, J., et al., *Carotid artery diameter in men and women and the relation to body and neck size.* Stroke, 2006. **37**(4): p. 1103-1105.

20. Dodge, J.T., et al., *Lumen diameter of normal human coronary arteries. Influence of age, sex, anatomic variation, and left ventricular hypertrophy or dilation.* Circulation, 1992. **86**(1): p. 232-246.

21. Macedo, R., et al., *MRI detects increased coronary wall thickness in asymptomatic individuals: The multi-ethnic study of atherosclerosis (MESA).* Journal of Magnetic Resonance Imaging, 2008. **28**(5): p. 1108-1115.

22. McPherson, D.D., et al., *High frequency epicardial echocardiography for coronary artery evaluation: In vitro and in vivo validation of arterial lumen and wall thickness measurements.* J Am Coll Cardiol, 1986. **8**(3): p. 600-606.

23. Miao, C., et al., *Positive Remodeling of the Coronary Arteries Detected by Magnetic Resonance Imaging in an Asymptomatic Population: MESA (Multi-Ethnic Study of Atherosclerosis).* J Am Coll Cardiol, 2009. **53**(18): p. 1708-1715.

24. Naylor, A.R., *Identifying the high-risk carotid plaque.* The Journal of Cardiovascular Surgery, 2014. **55**(2): p. 11-20.

25. ten Kate, G.L., et al., *Noninvasive Imaging of the Vulnerable Atherosclerotic Plaque.* Current problems in cardiology, 2010. **35**(11): p. 556-591.

26. de Weert, T.T., et al., *In Vivo Characterization and Quantification of Atherosclerotic Carotid Plaque Components With Multidetector Computed Tomography and Histopathological Correlation.* Arterioscler Thromb Vasc Biol, 2006. **26**(10): p. 2366-2372.

27. Kwee, R.M., et al., *Multimodality Imaging of Carotid Artery Plaques: 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography, Computed Tomography, and Magnetic Resonance Imaging.* Stroke, 2009. **40**(12): p. 3718-3724.

28. Obaid, D.R., et al., *Atherosclerotic Plaque Composition and Classification Identified by Coronary Computed Tomography: Assessment of Computed Tomography-Generated Plaque Maps Compared With Virtual Histology Intravascular Ultrasound and Histology.* Circulation: Cardiovascular Imaging, 2013: p. 655-664.

29. Papadopoulou, S.-L., et al., *Reproducibility of computed tomography angiography data analysis using semiautomated plaque quantification software: implications for the design of longitudinal studies.* Int J Cardiovasc Imaging, 2013. **29**(5): p. 1095-1104.

30. Papadopoulou, S.-L., et al., *Natural History of Coronary Atherosclerosis by Multislice Computed Tomography.* JACC: Cardiovascular Imaging, 2012. **5**(3, Supplement): p. S28-S37.

31. Rinehart, S., et al., *Quantitative measurements of coronary arterial stenosis, plaque geometry, and composition are highly reproducible with a standardized coronary arterial computed tomographic approach in high-quality CT datasets.* Journal of Cardiovascular Computed Tomography, 2011. **5**(1): p. 35-43.

32. Vukadinovic, D., *Automated Quantification of Atherosclerosis in CTA of Carotid Arteries*. 2012: Erasmus University Rotterdam.

33. Das, M., et al., *Carotid plaque analysis: comparison of dual-source computed tomography (CT) findings and histopathological correlation.* Eur J Vasc Endovasc Surg, 2009. **38**(1): p. 14-9.

34. Wintermark, M., et al., *High-Resolution CT Imaging of Carotid Artery Atherosclerotic Plaques.* American Journal of Neuroradiology, 2008. **29**(5): p. 875-882.

35. Sieren, J., et al., *Exploration of the volumetric composition of human lung cancer nodules in correlated histopathology and computed tomography.* Lung Cancer, 2011. **74**(1): p. 61-68.

36. Sheahan, M., et al., *Atherosclerotic Plaque Tissue: Noninvasive Quantitative Assessment of Characteristics with Software-aided Measurements from Conventional CT Angiography.* Radiology, 2017: p. 170127.